Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Feb 1 2023

Full Issue

Perspectives: US Must Reauthorize PEPFAR; PBMs Are Standing In The Way Of Biosimilars

Read recent commentaries about drug-cost issues.

The Washington Post: PEPFAR Has Made So Much Progress Against AIDS. We Can’t Let Up Now

Over the past two decades, PEPFAR has saved 25 million lives by providing more than $100 billion in funding for AIDS prevention and treatment. (Bill Gates, 1/28)

Stat: Paving The Way For A Watershed Year For Biosimilars 

January 31 is set to mark the start of a watershed year for the biosimilars industry with the release of Amjevita, the first biosimilar for Humira, the world’s best-selling drug. Several more Humira biosimilars will also be released this year. (Juliana M. Reed, 1/31)

Stat: As It Turns 40, The Orphan Drug Act For Rare Diseases Needs A Refresh

This month marks the 40th anniversary of the Orphan Drug Act. Since it was signed into law in 1983, the FDA has approved more than 1,100 treatments for rare diseases. (Emil D. Kakkis, 1/30)

Newsweek: Congress Should Address Health Care Monopolies 

A recent Gallup poll found that a whopping 18 million Americans—including 20 percent of Americans who make less than $24,000 annually—cannot afford at least one of their prescriptions. (Renee Ellmers, 1/30)

The Atlantic: The Weight-Loss-Drug Revolution Is A Miracle—And A Menace 

For years, the most popular weight-loss pills had earned their stigma. For example, the drug cocktail known as fen-phen was taken off the market for causing heart disease almost as reliably as it promoted healthy weight loss. (Derek Thompson, 1/27)

Also —

Newsweek: Gov. Noem's Threat To Prosecute Pharmacists Is Showboating 

South Dakota Gov. Kristi Noem's threats to prosecute pharmacists who dispense the abortion pill seems like showboating. (Rakim Brooks, 1/26)

Newsweek: It's Well Within State's Purview To Reject Abortion Pills

If indeed Governor Noem or any other Republican governor says that in their state abortion is illegal, which means abortion drugs are illegal, which means pharmacies cannot dispense them in the state, that is 100% within that state's purview to have that law. (Mark Davis, 1/26)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
  • Wednesday, April 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF